Robotic Surgery in Gynaecologic Oncology

The world of surgery is moving steadily toward minimally invasive techniques, and in gynaecology and gynaecologic oncology that shift now has a name: the Da Vinci robotic surgical system. The FDA approved the platform in 2000, the first robotic hysterectomy in gynaecology followed in 2005, and the technology has since extended into radical hysterectomies, lymphadenectomy and cytoreductive cancer surgery, alongside growing use in urology and general surgery. This guide draws on a Jivo Masterclass by Dr. Alka Dahiya, Senior Consultant in Gynaecological Surgical Oncology at BLK-Max Super Speciality Hospital, New Delhi, who has performed over 300 robotic cases across benign and oncological gynaecology.

A series built on one surgeon's practice, not a textbook

This series follows the structure of Dr. Dahiya's own masterclass: the mechanics of the Da Vinci system and why it outperforms laparoscopy on specific parameters, the operative setup and the deliberate exclusion of uterine manipulators from cancer cases, where robotic surgery earns its place in benign and oncological disease, the intraoperative principles that apply regardless of platform, ICG-guided sentinel lymph node dissection in endometrial cancer, four illustrative surgical cases, the outcomes data from 331 patients across two BLK-Max studies, the costs and limitations that still constrain adoption, and the training pathway for surgeons who want to practise this way.

The case for robotics, stated plainly

Robotic surgery offers 3D vision against the 2D image of standard laparoscopy, 7 degrees of freedom against 4, and EndoWrist instrument articulation that mimics the human wrist. The surgeon operates seated at a console rather than standing over a patient, which reduces fatigue across long procedures. Multiple studies cited in the masterclass found lower complication rates and higher lymph node yield in cytoreductive and cancer surgery compared with laparoscopy, along with lower rates of conversion to open surgery, particularly in obese patients or when bleeding occurs unexpectedly.

Not a blanket rule

Dr. Dahiya is explicit that robotic surgery is not applied to every patient. Benign indications such as complex hysterectomy, severe endometriosis and ovarian cystectomy suit the technology well. Oncological indications, from pre-invasive cervical disease to interval cytoreductive surgery for ovarian cancer, demand more careful case selection, because recurrence rate, surgical margins and lymph node yield cannot be compromised for the sake of a smaller incision.

What the evidence shows

Across 251 patients treated at BLK-Max for any gynaecological or gynaecologic oncological indication, including 160 with malignant disease, complication rates and hospital stay were both lower, with no compromise on oncological outcomes. A separate study of 80 patients with adnexal masses found three factors that predicted recurrence: residual disease, intraoperative spillage, and an ovarian cyst larger than 8 centimetres. A further study conducted with Intuitive quantified the annual impact on Dr. Dahiya's own practice: roughly 37 open surgeries avoided and 9 complications avoided each year.

Where the technology still has limits

Robotic surgery remains more expensive per procedure than laparoscopy and is not currently covered by most insurance providers or government panels in India. Operative time runs longer because of docking and setup, and the pool of trained surgeons is still small relative to demand. In oncology specifically, an inadvertent injury, spillage or a wrong call on patient selection in cervical or ovarian cancer can compromise outcomes and carries real medico-legal weight, which is why Dr. Dahiya returns repeatedly to the same point: choose the candidate carefully, every time.